人工智能用于结肠镜筛查的成本效益:建模研究。

Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study.

机构信息

RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, Porto, Portugal; Gastroenterology Department, Portuguese Oncology Institute of Coimbra, Coimbra, Portugal.

Clinical Effectiveness Research Group, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway; Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.

出版信息

Lancet Digit Health. 2022 Jun;4(6):e436-e444. doi: 10.1016/S2589-7500(22)00042-5. Epub 2022 Apr 13.

Abstract

BACKGROUND

Artificial intelligence (AI) tools increase detection of precancerous polyps during colonoscopy and might contribute to long-term colorectal cancer prevention. The aim of the study was to investigate the incremental effect of the implementation of AI detection tools in screening colonoscopy on colorectal cancer incidence and mortality, and the cost-effectiveness of such tools.

METHODS

We conducted Markov model microsimulation of using colonoscopy with and without AI for colorectal cancer screening for individuals at average risk (no personal or family history of colorectal cancer, adenomas, inflammatory bowel disease, or hereditary colorectal cancer syndrome). We ran the microsimulation in a hypothetical cohort of 100 000 individuals in the USA aged 50-100 years. The primary analysis investigated screening colonoscopy with versus without AI every 10 years starting at age 50 years and finishing at age 80 years, with follow-up until age 100 years, assuming 60% screening population uptake. In secondary analyses, we modelled once-in-life screening colonoscopy at age 65 years in adults aged 50-79 years at average risk for colorectal cancer. Post-polypectomy surveillance followed the simplified current guideline. Costs of AI tools and cost for downstream treatment of screening detected disease were estimated with 3% annual discount rates. The main outcome measures included the incremental effect of AI-assisted colonoscopy versus standard (no-AI) colonoscopy on colorectal cancer incidence and mortality, and cost-effectiveness of screening projected for the average risk screening US population.

FINDINGS

In the primary analyses, compared with no screening, the relative reduction of colorectal cancer incidence with screening colonoscopy without AI tools was 44·2% and with screening colonoscopy with AI tools was 48·9% (4·8% incremental gain). Compared with no screening, the relative reduction in colorectal cancer mortality with screening colonoscopy with no AI was 48·7% and with screening colonoscopy with AI was 52·3% (3·6% incremental gain). AI detection tools decreased the discounted costs per screened individual from $3400 to $3343 (a saving of $57 per individual). Results were similar in the secondary analyses modelling once-in-life colonoscopy. At the US population level, the implementation of AI detection during screening colonoscopy resulted in yearly additional prevention of 7194 colorectal cancer cases and 2089 related deaths, and a yearly saving of US$290 million.

INTERPRETATION

Our findings suggest that implementation of AI detection tools in screening colonoscopy is a cost-saving strategy to further prevent colorectal cancer incidence and mortality.

FUNDING

European Commission and Japan Society of Promotion of Science.

摘要

背景

人工智能(AI)工具可提高结肠镜检查中癌前息肉的检出率,并可能有助于长期预防结直肠癌。本研究旨在探讨在筛查性结肠镜检查中应用 AI 检测工具对结直肠癌发病率和死亡率的增量影响,以及此类工具的成本效益。

方法

我们使用基于人群的 Markov 模型微模拟方法,对无 AI 和有 AI 的结肠镜检查用于平均风险(无结直肠癌、腺瘤、炎症性肠病或遗传性结直肠癌综合征的个人或家族史)个体的结直肠癌筛查进行了研究。我们在一个假设的美国 10 万名 50-100 岁个体队列中进行了微模拟。主要分析比较了每 10 年进行一次的有无 AI 的筛查性结肠镜检查(起始年龄 50 岁,截止年龄 80 岁),并假设 60%的筛查人群参与,随访至 100 岁。在次要分析中,我们对平均风险的 50-79 岁成年人进行了一生中一次的 65 岁结肠镜检查筛查。息肉切除后的监测遵循简化的现行指南。AI 工具的成本和筛查发现疾病的下游治疗费用以 3%的年贴现率进行估计。主要结局指标包括与标准(无 AI)结肠镜检查相比,AI 辅助结肠镜检查对结直肠癌发病率和死亡率的增量影响,以及针对美国平均风险筛查人群的筛查成本效益。

结果

在主要分析中,与不筛查相比,无 AI 的筛查性结肠镜检查可使结直肠癌发病率相对降低 44.2%,有 AI 的筛查性结肠镜检查可使结直肠癌发病率相对降低 48.9%(增加 4.8%)。与不筛查相比,无 AI 的筛查性结肠镜检查可使结直肠癌死亡率相对降低 48.7%,有 AI 的筛查性结肠镜检查可使结直肠癌死亡率相对降低 52.3%(增加 3.6%)。AI 检测工具使每个筛查个体的贴现成本从 3400 美元降至 3343 美元(每人节省 57 美元)。在对一生中一次的结肠镜检查进行的二次分析中,结果相似。在人群层面上,在筛查性结肠镜检查中应用 AI 检测每年可额外预防 7194 例结直肠癌病例和 2089 例相关死亡,并节省 2.9 亿美元。

结论

我们的研究结果表明,在筛查性结肠镜检查中应用 AI 检测工具是一种节约成本的策略,可以进一步降低结直肠癌的发病率和死亡率。

资助

欧盟委员会和日本学术振兴会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索